MedElevator Войти в исследования
← Поиск публикаций

DOI 10.18632/oncotarget.11019

Медицинская библиотека · Oncotarget · 2016

Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies.

Chen Kevin H, Wada Masayuki, Firor Amelia E, Pinz Kevin G, Jares Alexander, Liu Hua, Salman Huda, Golightly Marc, Lan Fengshuo, Jiang Xun, Ma Yupo

СтатьяПеревод в очереди

Аннотация

OBJECTIVES

To determine thresholds for rheumatoid arthritis (RA) magnetic resonance imaging scores (RAMRIS) associated with a low risk of structural damage progression.

METHODS

MRI of the dominant hand was performed and RAMRIS scores determined at weeks 0, 24, and 52. X-rays were performed and van der Heijde-Sharp scores (vdHS) determined. In a development cohort (n=297) the changes in MRI erosion score and vdHS score were determined over the 24-week to 52-week interval and progression was defined as change >0.5. We identified 24-week thresholds for synovitis and osteitis that provided >90% sensitivity for imaging progression over the 24 to 52-week interval. The performance of these cut-offs was tested in a validation cohort (n=217).

RESULTS

In the development cohort, synovitis or osteitis scores ≤3 by 24 weeks were associated with a low probability of progression on MRI and x-ray. The coefficient for osteitis was stronger than that of synovitis in models predicting x-ray and MRI progression. Therefore, a total inflammation score was weighted on osteitis (x2). An inflammation score ≤9 was more frequently attained than DAS28 remission (64 vs. 38) and was associated with low probability of progression regardless of attainment of clinical remission. In the validation cohort, there was a low odds of MRI progression among those with low synovitis [OR 0.27 (0.086,0.82) p=0.02], osteitis [OR 0.20 (0.085, 0.49) p<0.001] and inflammation scores [OR 0.12 (0.033, 0.41) p=0.001].

CONCLUSIONS

Attainment of low MRI single-hand synovitis and osteitis is not uncommon and predicts a lack of structural progression in RA, independent of clinical remission.

Для цитирования: Chen Kevin H, Wada Masayuki, Firor Amelia E, Pinz Kevin G, Jares Alexander, Liu Hua, Salman Huda, Golightly Marc, Lan Fengshuo, Jiang Xun, Ma Yupo. Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies.. Oncotarget. 2016. DOI: 10.18632/oncotarget.11019.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.